دواعي استعمال بيوري نيثول 50مجم 25 قرص

Mercaptopurine 50 mg tablets, 25 tablets (Aspen; imported via Egyptian Pharmaceutical Trading Company). Cytotoxic antimetabolite for acute leukaemia.

• Acute lymphoblastic leukaemia (ALL)الفئة: Adults, adolescents and childrenHealth Products Regulatory Authority (HPRA), Ireland
• Acute promyelocytic leukaemia (APL) / acute myeloid leukaemia M3الفئة: Adults, adolescents and childrenHealth Products Regulatory Authority (HPRA), Ireland

• Hypersensitivity to mercaptopurine or excipients; concomitant yellow fever vaccine.نشرة دولية لنفس التركيبة · Health Products Regulatory Authority (HPRA), Ireland

• Strongly myelosuppressive cytotoxic: full blood counts (daily during remission induction) and careful monitoring; interrupt at the first abnormally large fall in counts.نشرة دولية لنفس التركيبة · Health Products Regulatory Authority (HPRA), Ireland
• TPMT deficiency and NUDT15 variants increase the risk of severe toxicity and generally require dose reduction.نشرة دولية لنفس التركيبة · Health Products Regulatory Authority (HPRA), Ireland
• Hepatotoxic: monitor liver function tests weekly; stop immediately if jaundice develops.نشرة دولية لنفس التركيبة · Health Products Regulatory Authority (HPRA), Ireland
• Avoid live vaccines; increased risk of infections, lymphoproliferative disorders and skin cancers; limit sun/UV exposure.نشرة دولية لنفس التركيبة · Health Products Regulatory Authority (HPRA), Ireland

• Allopurinol, oxipurinol, thiopurinol (xanthine oxidase inhibitors)Give only 25% of the usual mercaptopurine dose; avoid febuxostat.Health Products Regulatory Authority (HPRA), Ireland
• Oral anticoagulantsReinforced INR monitoring is recommended.Health Products Regulatory Authority (HPRA), Ireland
• Olsalazine, mesalazine, sulfasalazine (TPMT inhibitors)May exacerbate myelosuppression.Health Products Regulatory Authority (HPRA), Ireland
• RibavirinCo-administration not advised: may reduce efficacy and increase toxicity.Health Products Regulatory Authority (HPRA), Ireland

• Do not give in pregnancy without careful risk-benefit assessment; substantial transplacental transfer occurs. Men and women should use effective contraception during treatment and for at least 3 months after the last dose.نشرة دولية لنفس التركيبة · Health Products Regulatory Authority (HPRA), Ireland

• Full blood count, liver function tests (weekly) and, during remission induction, uric acid in blood and urine.نشرة دولية لنفس التركيبة · Health Products Regulatory Authority (HPRA), Ireland